The drug development space is continuing to attract more and more investment. On Thursday, another major player Generate Biomedicines announced a $370 million Series B round. Generate Biomedicines is touting an platform-based approach to drug development, but with its own spin: a focus on proteins. Generate’s thesis is simple: rather than making connections between targets […]...